following an abbreviated submission:
trametinib (Mekinist®) is accepted for restricted use within NHSScotland.
Indication under review: in combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
SMC restriction: after first line treatment
Trametinib in combination with dabrafenib offers an additional treatment choice in the therapeutic class of BRAF/ mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors.
Another medicine combination within this therapeutic class has been accepted via the end of life and orphan medicine process.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
SMC has previously accepted trametinib for restricted use in combination with dabrafenib for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (SMC 1161/16). The current advice now extends use after first line treatment.
Trametinib is also licensed as monotherapy. As the company submission related only to combination therapy, SMC cannot recommend use as monotherapy.
Download detailed advice730KB (PDF)
- Medicine name:
- trametinib (Mekinist)
- SMC ID:
For treatment in combination with dabrafenib (Tafinlar) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. This is an abbreviated submission to remove the SMC restriction to first-line treatment.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 08 March 2021